Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 31;13(11):1562.
doi: 10.3390/jpm13111562.

Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series

Affiliations

Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series

Leonard B Weinstock et al. J Pers Med. .

Abstract

Mast cell activation syndrome (MCAS) is an immune disease with an estimated prevalence of 17%. Mast cell chemical mediators lead to heterogeneous multisystemic inflammatory and allergic manifestations. This syndrome is associated with various neurologic and psychiatric disorders, including headache, dysautonomia, depression, generalized anxiety disorder, and many others. Although MCAS is common, it is rarely recognized, and thus, patients can suffer for decades. The syndrome is caused by aberrant mast cell reactivity due to the mutation of the controller gene. A case series is presented herein including eight patients with significant neuropsychiatric disorders that were often refractory to standard medical therapeutics. Five patients had depression, five had generalized anxiety disorder, and four had panic disorder. Other psychiatric disorders included attention-deficit hyperactivity disorder, obsessive compulsive disorder, phobias, and bipolar disorder. All eight patients were subsequently diagnosed with mast cell activation syndrome; six had comorbid autonomic disorders, the most common being postural orthostatic tachycardia syndrome; and four had hypermobile Ehlers-Danlos syndrome. All patients experienced significant improvements regarding neuropsychiatric and multisystemic symptoms after mast-cell-directed therapy. In neuropsychiatric patients who have systemic symptoms and syndromes, it is important to consider the presence of an underlying or comorbid MCAS.

Keywords: POTS; anxiety; depression; dysautonomia; mast cell activation syndrome; panic disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Photo of the periorbital edema with facial and neck flushing provided by patient 1.

Similar articles

Cited by

References

    1. Afrin L.B., Butterfield J.H., Raithel M., Molderings G.J. Often seen, rarely recognized: Mast cell activation disease—A guide to diagnosis and therapeutic options. Ann. Med. 2016;48:190–201. doi: 10.3109/07853890.2016.1161231. - DOI - PubMed
    1. Afrin L.B., Self S., Menk J., Lazarchick J. Characterization of Mast Cell Activation Syndrome. Am. J. Med. Sci. 2017;353:207–215. doi: 10.1016/j.amjms.2016.12.013. - DOI - PMC - PubMed
    1. Hamilton M.J. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence. Immunol. Allergy Clin. N. Am. 2018;38:469–481. doi: 10.1016/j.iac.2018.04.002. - DOI - PMC - PubMed
    1. Afrin L.B., Pöhlau D., Raithel M., Haenisch B., Dumoulin F.L., Homann J., Mauer U.M., Harzer S., Molderings G.J. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav. Immun. 2015;50:314–321. doi: 10.1016/j.bbi.2015.07.002. - DOI - PubMed
    1. Molderings G.J., Haenisch B., Bogdanow M., Fimmers R., Nöthen M.M. Familial Occurrence of Systemic Mast Cell Activation Disease. PLoS ONE. 2013;8:e76241. doi: 10.1371/journal.pone.0076241. - DOI - PMC - PubMed

LinkOut - more resources